GENMAB ACQUIRES WORLDWIDE RIGHTS FOR HUMAX-CD4

Genmab A/S has announced that it has licensed from Medarex the European and Asian rights to utilize Medarex's UltiMAb technology to develop and commercialize antibodies raised against the CD4 antigen, including HuMax-CD4, a fully human antibody that Genmab currently has in Phase III clinical studies to treat cutaneous T-cell lymphoma. With the acquisition of this new territory, Genmab now holds worldwide rights to HuMax-CD4. Under the terms of the agreement, Genmab has agreed to pay Medarex an upfront payment of $2 million, and Medarex is entitled to potential total milestone and license fee payments of $12.5 million, as well as royalties that could reach double digits for a successfully commercialized product in the new territories.

Yahoo News (http://biz.yahoo.com/prnews/050630/phth012.html?.v=15)